Liver Diseases
Welcome,         Profile    Billing    Logout  
 309 Companies   473 Products   473 Products   224 Mechanisms of Action   25 Trials   4900 News 


«12...7891011121314151617...9899»
  • ||||||||||  Civacir (hepatitis C immune globulin) / ADMA Biologics, Kedrion
    Trial completion:  Civacir (clinicaltrials.gov) -  Sep 1, 2016   
    P3,  N=80, Completed, 
    Active, not recruiting --> Completed
  • ||||||||||  OrienX010 / OrienGene
    Trial completion, Trial primary completion date:  A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer (clinicaltrials.gov) -  Sep 1, 2016   
    P1,  N=18, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Oct 2013 --> May 2014
  • ||||||||||  Tabrecta (capmatinib) / Incyte, Novartis
    Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date, Metastases:  Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Sep 1, 2016   
    P2,  N=0, Withdrawn, 
    Recruiting --> Completed | Trial primary completion date: Oct 2013 --> May 2014 N=69 --> 0 | Initiation date: Mar 2014 --> Dec 2016 | Suspended --> Withdrawn | Trial primary completion date: Sep 2016 --> Jul 2019
  • ||||||||||  aldafermin (NGM282) / NGM Biopharma
    Trial completion, Phase classification, Enrollment change, Trial primary completion date:  Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) -  Aug 24, 2016   
    P2b,  N=36, Completed, 
    Trial primary completion date: Dec 2016 --> Oct 2017 Recruiting --> Completed | Phase classification: P2 --> P2b | N=45 --> 36 | Trial primary completion date: Jun 2015 --> Feb 2016
  • ||||||||||  carotuximab IV (ENV-105) / Kairos Pharma
    Trial primary completion date, Combination therapy, IO biomarker:  Sorafenib and TRC105 in Hepatocellular Cancer (clinicaltrials.gov) -  Aug 24, 2016   
    P1/2,  N=44, Recruiting, 
    Recruiting --> Completed | Phase classification: P2 --> P2b | N=45 --> 36 | Trial primary completion date: Jun 2015 --> Feb 2016 Trial primary completion date: Sep 2016 --> Sep 2017
  • ||||||||||  Enrollment change, Trial termination, MRI:  3-Tesla MRI Response to TACE in HCC (Liver Cancer) (clinicaltrials.gov) -  Aug 23, 2016   
    P=N/A,  N=2, Terminated, 
    Active, not recruiting --> Completed N=38 --> 2 | Recruiting --> Terminated; Funding unavailable
  • ||||||||||  Aphthasol (amlexanox) / Abeona Therap, Esteve
    Clinical protocol, Enrollment closed:  Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients (clinicaltrials.gov) -  Aug 23, 2016   
    P2,  N=40, Active, not recruiting, 
    Trial primary completion date: May 2016 --> Nov 2016 Recruiting --> Active, not recruiting
  • ||||||||||  Trial completion, Enrollment change:  Relationship of Metabolic Abnormalities to Hepatic Steatosis in HIV (clinicaltrials.gov) -  Aug 20, 2016   
    P=N/A,  N=12, Completed, 
    Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Feb 2016 Active, not recruiting --> Completed | N=40 --> 12
  • ||||||||||  midodrine hydrochloride / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date:  MAFRI: Midodrine and Albumin for Cirrhotic Patients With Functional Renal Impairment (clinicaltrials.gov) -  Aug 19, 2016   
    P2,  N=7, Completed, 
    Active, not recruiting --> Completed | N=40 --> 12 Recruiting --> Completed | N=20 --> 7 | Trial primary completion date: Dec 2015 --> Jun 2016
  • ||||||||||  Pegasys (pegylated interferon ? -2a) / Roche
    Trial completion, Trial initiation date, Trial primary completion date:  A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon (clinicaltrials.gov) -  Aug 17, 2016   
    P=N/A,  N=500, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Initiation date: Jan 2012 --> Sep 2011 | Trial primary completion date: Jan 2015 --> Aug 2014
  • ||||||||||  pamrevlumab (FG-3019) / FibroGen
    Enrollment change, Trial termination, Trial primary completion date:  A Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection (clinicaltrials.gov) -  Aug 16, 2016   
    P2,  N=114, Terminated, 
    Recruiting --> Completed | Initiation date: Jan 2012 --> Sep 2011 | Trial primary completion date: Jan 2015 --> Aug 2014 N=228 --> 114 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Jun 2015; Study terminated due to an unexpected prominent effect of entecavir alone in this patient population.
  • ||||||||||  Trial completion, Trial primary completion date:  Computertomography-guided Wire Marking of the Liver (clinicaltrials.gov) -  Aug 16, 2016   
    P=N/A,  N=20, Completed, 
    N=228 --> 114 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Jun 2015; Study terminated due to an unexpected prominent effect of entecavir alone in this patient population. Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016
  • ||||||||||  oxaliplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    Enrollment closed, Metastases:  Combination Treatment for Advanced Liver Cancer (clinicaltrials.gov) -  Aug 2, 2016   
    P3,  N=98, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  Trial completion, Enrollment change:  Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease (clinicaltrials.gov) -  Aug 2, 2016   
    P=N/A,  N=25, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | N=33 --> 25
  • ||||||||||  Tyzeka (telbivudine) / Novartis
    Enrollment open, Enrollment change, Combination therapy:  TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction (clinicaltrials.gov) -  Aug 2, 2016   
    P1/2,  N=120, Enrolling by invitation, 
    Recruiting --> Completed | N=33 --> 25 Active, not recruiting --> Enrolling by invitation | N=90 --> 120
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines (clinicaltrials.gov) -  Aug 1, 2016   
    P4,  N=35000, Completed, 
    Active, not recruiting --> Enrolling by invitation | N=90 --> 120 Active, not recruiting --> Completed | N=6000 --> 35000 | Trial primary completion date: Mar 2017 --> Dec 2015
  • ||||||||||  Pegasys (pegylated interferon α -2a) / Roche
    Trial completion:  Effect of Camel Milk on Chronic Hepatitis C (clinicaltrials.gov) -  Jul 30, 2016   
    P2,  N=40, Completed, 
    Active, not recruiting --> Completed | N=6000 --> 35000 | Trial primary completion date: Mar 2017 --> Dec 2015 Recruiting --> Completed
  • ||||||||||  Enrollment closed, Enrollment change:  I-TRIGER: INR-Triggered Transfusion In GI Bleeders From ER (clinicaltrials.gov) -  Jul 25, 2016   
    P3,  N=50, Active, not recruiting, 
    Trial primary completion date: Dec 2015 --> Dec 2018 Recruiting --> Active, not recruiting | N=72 --> 50
  • ||||||||||  Enrollment closed, Trial primary completion date:  High Fructose Corn Syrup (clinicaltrials.gov) -  Jul 24, 2016   
    P=N/A,  N=30, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=72 --> 50 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Feb 2017
  • ||||||||||  lenalidomide / Generic mfg.
    Enrollment closed, Trial primary completion date, Metastases:  Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Jul 23, 2016   
    P2,  N=55, Active, not recruiting, 
    N=252 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2016 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Oct 2016